Market news

Becton, Dickinson and Company will release its third-quarter earnings next month, and analysts anticipate a double-digit profit dip.

Becton Dickinson (BDX) is back on investors’ radar after a reshuffle in Russell indices, with the stock added to the Russell Midcap Index and Russell Midcap Value Benchmark and removed from two Russell Top 200 indices. See our latest analysis for Becton Dickinson. At a share price of $150.56, Becton Dickinson has seen its 1 day share price return decline 3.67%, while the year to date share price return is down 22.77%. However, the 1 year total shareholder return of 11.85% suggests longer term...

Becton Dickinson stock has fallen 22.8% year to date, yet the valuation checks and an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach both suggest the shares may now be trading at a discount to what the underlying cash flows imply. The share price is down 22.8% so far this year, which has opened up a gap between recent performance and what current valuation metrics indicate. The recent Vizient Innovative Technology contract for the CentroVena One Insertion System can...

Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Don't sleep on these medical device leaders.